Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

2.905 -0.135 (-4.44%)
Streaming Delayed Price Updated: 10:13 AM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Esperion Therapeutics, Inc. - Common Stock

News headline image
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Jefferies Global Healthcare Conference - London
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report Third Quarter 2025 Financial Results on November 6
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Pricing of Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Proposed Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Upcoming September Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report Second Quarter 2025 Financial Results on August 5
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Appoints Craig Thompson to Board of Directors
Brings More Than Twenty Years of Biopharmaceutical Leadership Experience 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Upcoming June Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.